Corcept Therapeutics Incorporated (CORT) financial statements (2021 and earlier)

Company profile

Business Address 149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments441429405307276232202
Cash and cash equivalents76315984314558
Short-term investments365398347223245187143
Receivables27242428202220
Inventory, net of allowances, customer advances and progress billings5555555
Inventory5555555
Prepaid expense 2     
Other undisclosed current assets5544686
Total current assets:479463438345307267233
Noncurrent Assets
Inventory, Noncurrent16121111121213
Operating lease, right-of-use asset3333311
Property, plant and equipment2111111
Long-term investments and receivables3615442393524
Long-term investments3615442393524
Deferred income tax assets32343541465157
Other noncurrent assets5553300
Total noncurrent assets:93715910110510096
TOTAL ASSETS:572534498445412367329
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32252925312823
Accounts payable11765867
Accrued liabilities21192320232216
Debt   2211
Other undisclosed current liabilities1618138646
Total current liabilities:47434234393230
Noncurrent Liabilities
Long-term debt and lease obligation11122  
Operating lease, liability11122  
Liabilities, other than long-term debt0000000
Accounts payable and accrued liabilities0000000
Total noncurrent liabilities:1122200
Total liabilities:48444436413331
Stockholders' equity
Stockholders' equity attributable to parent523490454409371334298
Common stock0000000
Treasury stock, value(76)(64)(64)(63)(63)(60)(60)
Additional paid in capital516496482466457447437
Accumulated other comprehensive income0110000
Retained earnings (accumulated deficit)8256357(24)(53)(79)
Total stockholders' equity:523490454409371334298
TOTAL LIABILITIES AND EQUITY:572534498445412367329

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues86868993888272
Cost of revenue
(Cost of Goods and Services Sold)
(1)(1)(1)(2)(1)(1)(1)
Gross profit:84858791868071
Operating expenses(54)(60)(52)(54)(51)(47)(46)
Operating income:31253538353325
Nonoperating income 111 11
Other undisclosed income from continuing operations before equity method investments, income taxes0   1  
Income from continuing operations before income taxes:31253639363426
Income tax expense(5)(4)(8)(9)(7)(8)(6)
Net income available to common stockholders, diluted:26222830292620

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income:26222830292620
Other undisclosed comprehensive income0   0  
Comprehensive income:26222830302620
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)10(0)(0)0
Comprehensive income, net of tax, attributable to parent:26212930292620

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: